set enrichment analysis and expression pattern exploration implicate an involvement of neurodevelopmental processes in bipolar disorder, Journal of Affective Disorders, https://doi.org/10.1016/j.jad. 2017.11.068 This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of the resulting galley proof before it is published in its final citable form. Please note that during the production process errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain. 
INTRODUCTION
Bipolar disorder (BD) is a genetically complex mental illness. During the past ten years, several genome-wide association studies (GWAS) of BD were conducted and have identified 19 loci harboring common genetic susceptibility variants (Sullivan et al., 2017) . It is assumed that with growing sample sizes the number of loci will increase, as has been successfully demonstrated for schizophrenia, where GWAS in 61,000 patients found 155 independent loci (Sullivan et al., 2017) .
Gene set enrichment analysis (GSEA) is a powerful tool to retrieve more biological information from existing GWAS. Such multi-locus approaches utilize functional frameworks of ontologies or pathways to integrate genes at strongly to moderately associated loci. Using the same sample size, GSEA therefore has greater statistical power to detect a polygenic contribution of individually small effects to overall risk than single-locus analyses (Lee et al., 2012) .
Here, we applied GSEA algorithms to a large published GWAS on BD, including approximately 9,700 patients and 14,200 controls (Mühleisen et al., 2014) . We found associations between BD and two signaling pathways involved in brain development.
METHODS AND MATERIALS

Phenotype and SNP Data
For GSEA, we used combined data from the Systematic Investigation of the Molecular
Causes of Major Mood Disorders and Schizophrenia (MooDS) and Psychiatric
Genomics Consortium (PGC) consortia comprising 2,267,487 autosomal singlenucleotide polymorphisms (SNPs) from 9,747 patients with life-time diagnoses of BD and 14,278 controls, as described by Mühleisen et al. (2014) . Written informed consent was obtained from all patients and controls before participation in the study.
Gene Set Enrichment Analyses
For discovery, we used Meta-Analysis Gene-set Enrichment of variaNT Associations (MAGENTA; (Segrè et al., 2010) For secondary analysis of the significantly enriched pathways, we applied Gene Set Analysis SNP (GSA-SNP; (Nam et al., 2010) ) on the same input data. GSA-SNP uses p-values of SNPs to calculate enrichment scores by using the Z-statistic method. But instead of using the maximum effect per gene as a proxy for the respective gene, we chose the second-best p-value to represent the effect of each gene to avoid spurious associations (Kwon et al., 2012) .
For pathways, we used curated target gene sets (pathways) from Reactome as available through the Molecular Signature Database (v6.0; (Subramanian et al., 2005) .
Their sizes were restricted from 20 to 200 to avoid overly narrow or broad gene sets.
This resulted in 397 sets for GSEA.
Gene expression data
BrainScope enables interactive visual exploration of spatial and temporal human brain transcriptomes from the Allen Institute for Brain Science (Huisman et al., 2017 ). Here we focused on the dataset Developmental Transcriptome from the BrainSpan atlas that had been pre-processed and re-analyzed by BrainScope's developers resulting in the dataset Developing human (comparative explorer) with RNA expression levels of 18,233 genes (Entrez Gene definitions) that were z-score normalized, to have a zero mean and a standard deviation of 1.
To explore changes of co-expressed genes in brain regions and time windows, we used heat maps of the comparative explorer from BrainScope under default settings. Each square of a heat map displayed the average regional expression of the selected gene(s) across pooled tissue samples (replicates, developmental stages) from donor brains (controls). For BD-associated pathways from GSEA results, heat maps were assembled and annotated using standard graphical software. The brain regions covered neocortical areas including primary cortices (auditory, motor, somatosensory, visual), pre-and orbitofrontal cortices, the temporal cortex (inferolateral, posterior superior), the parietal cortex (posteroventral); principal structures of the diencephalon including parts of the basal ganglia (amygdala, striatum) and limbic system (anterior cingulate, amygdala, hippocampus) coiled around and connected to thalamus and hypothalamus; the hindbrain (cerebellar cortex). The time windows comprised fetal development (from early 2nd trimester to birth), infancy (from birth to one year), childhood (from two to eleven years), adolescence (from 13 to 19 years), and adulthood (from 21 to 40 years).
BrainScope, BrainSpan, and Entrez Gene are publicly accessible at www.brainscope.nl, www.brainspan.org, and www.ncbi.nlm.nih.gov/gene.
RESULTS
Discovery and validation of BD-associated pathways
GSEA by MAGENTA on MooDS-PGC data revealed two study-wide significant
Reactome pathways when applying the significance criterion of FDR < 0.05 ( Table 1) . 
NRAS, CREB1, KRAS, CACNB3, COL2A1, CACNB2, MAPK1, SPTBN1). Three significant genes were common to both pathways (NRAS, KRAS, MAPK1).
The associated genes showed a balanced contribution to the total significance of the two target gene sets (Supplementary Table 1 ). The subsequent GSEA by GSA-SNP on the same input data validated the enrichments in the two target gene sets (P=4.80E-06 and P=3.28E-08, respectively; Table 1 ).
Exploration of gene expression in BD-associated pathways
To assess patterns of co-expressed genes from both pathways in the developing and adult brain, we used data from BrainSpan accessed through BrainScope and screened necessary to achieve sufficient statistical power to identify them (Sullivan et al., 2017) .
In the present analysis, we chose to apply GSEA to our GWAS data because this approach should have greater statistical power to detect a polygenic contribution of individually small effects to overall risk than single-locus analyses (Lee et al., 2012) . To further strengthen our findings, we investigated genes within the implicated pathways for expression at milestones of normal brain development to obtain information on their relevance during ontogenetic stages. Biological pathway studies of BD so far have found evidence for genes involved in calcium channels, hormonal regulation, glutamate signaling, neural development, and histone methylation (Nurnberger et al., 2014; O'Dushlaine et al., 2015) .
Our strongest finding was GRB2 events in ERBB2 signaling which functions to promote cell proliferation, survival, and differentiation, not only in the brain. Biologically, an association with ERBB2, EGFR, and HBEGF is plausible because they form a ligandactivated receptor complex for signaling and thus seem to be key players of that pathway. The importance of ERBB2 in BD is further supported by a genome-wide significant association finding (Hou et al., 2016) and by the observation of dysregulated ERBB2 expression in the dorsolateral prefrontal cortex in both BD and schizophrenia (Shao and Vawter, 2008) . This expression alteration is significantly related to lifetime antipsychotic exposure, supporting ERBB2 as target for clinical research. ErbB2/B4-deficient mice exhibit elevated aggression and reduced prepulse inhibition that both can be rescued by clozapine treatment, a frequently used antipsychotic medication (Barros et al., 2009) . EGFR (alias ERBB1) is reported to play an essential role in axon myelination during the first postnatal weeks and can therefore be considered as an important regulator of neurodevelopment (Aguirre et al., 2007) . The gene was also supported by single SNP and haplotype analysis in a GWAS of BD (Sklar et al., 2008) .
HBEGF is a EGF-like binding partner of EGFR and mice lacking Hb-egf in the ventral forebrain showed abnormalities in psychomotor behavior and neurotransmission which can be ameliorated by typical or atypical antipsychotics (Oyagi et al., 2009 ).
Our second finding was NCAM signaling for neurite out-growth which modulates neural differentiation and synaptic plasticity. Homophilic binding of NCAM1 molecules at the cell-surface induces signaling that leads to cell-cell adhesion and axon elongation.
Association with NCAN in this pathway is of major importance since experiments in rats have demonstrated that interference of Ncam1-Ncam1 bindings by concurrent Ncan inhibits these cellular processes (Retzler et al., 1996) . NCAN encodes an extracellular matrix proteoglycan and has been described as important susceptibility gene for BD (Cichon et al., 2011) . Furthermore, NCAN was reported to be associated with brain development in health and disease, specifically to gray matter loss in central limbic regions and higher folding in the lateral occipital and prefrontal cortex suggesting impairments of emotion perception and regulation and top-down cognitive functioning (Dannlowski et al., 2015) . Behavioral abnormalities in Ncan-deficient mice show striking similarities with mania symptoms in humans that can be rescued by lithium treatment, an established mood stabilizer (Miró et al., 2012) . Association with CACNB2 and CACNB3 represents another highlight of this pathway, since abnormal calcium channel activity is considered to be important for BD (Nurnberger et al., 2014) . Unexpectedly, CACNA1C was not found among enriched pathway genes, despite strong support of this gene from SNP data. Further evaluation revealed that CACNA1C was absent from the pathway definition. A possible link to our other finding exists through a gene overlap of KRAS, NRAS and MAPK1 as well as binding between NCAM1 and EGFR.
In both pathways, most genes showed high co-expression during fetal development and infancy in many neocortical and subcortical areas indicating co-expression and possibly co-working of encoded protein functions. These observations provide links to brain regions where known pathophysiological changes in BD patients occur, for instance, in the limbic system which is concerned with many aspects of emotion and behavior.
Limitations
Although both pathway findings were technically reproduced by two different approaches and are based on one of the largest GWAS data of BD so far, association replication in independent samples was not attempted. Gene expression was explored in control brains only, which may show co-expression differences compared with BD brains. Follow-up studies are required to further evaluate the relevance of our findings for etiological and clinical aspects of BD.
Conclusion
The present study found evidence for associations between BD and two signaling pathways. Integration of evidence from genetic studies, brain developmental expression patterns and molecular functions of these pathways support the hypothesis that neurodevelopmental processes play an important role in the etiology of BD. 
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